Edward A Neuwelt Selected Research

gadoteridol (Prohance)

1/2018	Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas.
3/2013	Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
8/2012	Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
2/2011	Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
2/2011	Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward A Neuwelt Research Topics

Disease

58	Neoplasms (Cancer) 01/2022 - 04/2002
24	Brain Neoplasms (Brain Tumor) 01/2022 - 04/2002
17	Lymphoma (Lymphomas) 03/2020 - 09/2002
14	Glioma (Gliomas) 01/2018 - 10/2003
12	Glioblastoma (Glioblastoma Multiforme) 05/2022 - 01/2005
12	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2005
8	Ototoxicity 01/2020 - 07/2004
7	Hearing Loss (Hearing Impairment) 01/2020 - 04/2012
5	Medulloblastoma 01/2022 - 04/2012
4	Inflammation (Inflammations) 01/2020 - 10/2005
4	Central Nervous System Diseases (CNS Diseases) 06/2017 - 01/2007
4	Breast Neoplasms (Breast Cancer) 01/2015 - 01/2007
4	Carcinoma (Carcinomatosis) 06/2013 - 05/2004
3	Hypoxia (Hypoxemia) 05/2022 - 01/2008
3	Neuroinflammatory Diseases 01/2021 - 01/2016
3	Edema (Dropsy) 02/2015 - 04/2009
2	Neutropenia 01/2021 - 01/2017
2	Anemia 01/2021 - 04/2016
2	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2010
2	Macular Degeneration (Age-Related Maculopathy) 01/2021 - 01/2020
2	Hepatoblastoma 06/2018 - 10/2009
2	Renal Insufficiency (Renal Failure) 10/2017 - 10/2011
2	Chronic Renal Insufficiency 10/2017 - 03/2009
2	Nausea 04/2016 - 08/2006
2	Multiple Sclerosis 06/2015 - 10/2005
2	Neuroblastoma 02/2015 - 01/2008
2	Nephrogenic Fibrosing Dermopathy 07/2013 - 03/2009
2	Liver Neoplasms (Liver Cancer) 06/2013 - 10/2009
2	Neurologic Manifestations (Neurological Manifestations) 04/2013 - 02/2005
2	B-Cell Lymphoma (Lymphoma, B Cell) 04/2011 - 09/2002
2	Leukoencephalopathies 11/2006 - 02/2005
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2005 - 02/2005
1	Thrombosis (Thrombus) 01/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022
1	Choroidal Neovascularization 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Geographic Atrophy 01/2021
1	Leukopenia 01/2021
1	Astrocytoma (Pilocytic Astrocytoma) 01/2021

Drug/Important Bio-Agent (IBA)

25	Ferrosoferric Oxide (Magnetite)FDA Link 01/2022 - 04/2007
20	Contrast MediaIBA 12/2020 - 04/2002
15	GadoliniumIBA 12/2020 - 04/2002
15	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 07/2004
9	Pharmaceutical PreparationsIBA 01/2020 - 05/2002
9	Bevacizumab (Avastin)FDA Link 01/2018 - 04/2009
8	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 09/2002
7	Monoclonal AntibodiesIBA 03/2020 - 10/2003
7	sodium thiosulfate FDA Link 06/2018 - 05/2004
7	PlatinumIBA 10/2017 - 07/2004
7	Carboplatin (JM8)FDA LinkGeneric 01/2014 - 05/2004
7	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 07/2013 - 04/2002
6	Acetylcysteine (Siran)FDA LinkGeneric 10/2017 - 05/2004
5	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2010
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2005
5	IronIBA 12/2019 - 04/2002
5	gadoteridol (Prohance)FDA Link 01/2018 - 02/2011
5	IntegrinsIBA 01/2017 - 01/2011
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 03/2013
4	intetumumabIBA 01/2017 - 01/2011
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015 - 01/2011
4	ferric oxide (iron oxide)IBA 11/2006 - 04/2002
3	Rituximab (Mabthera)FDA Link 03/2020 - 10/2009
3	Oxygen (Dioxygen)IBA 01/2018 - 01/2011
3	Sulfhydryl Compounds (Thiols)IBA 01/2014 - 06/2002
3	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2014 - 10/2009
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2013
2	CytokinesIBA 01/2020 - 07/2012
2	AntioxidantsIBA 01/2017 - 02/2015
2	ErbB Receptors (EGF Receptor)IBA 01/2015 - 01/2005
2	antiarrhythmic peptide (AAP)IBA 01/2014 - 10/2009
2	Glutathione (Reduced Glutathione)IBA 06/2013 - 10/2009
2	gadodiamide (Omniscan)FDA Link 12/2011 - 04/2009
2	etoposide phosphate (Etopophos)FDA Link 01/2010 - 05/2004
2	Melphalan (Alkeran)FDA LinkGeneric 01/2010 - 05/2004
2	Small Interfering RNA (siRNA)IBA 05/2009 - 01/2008
2	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2009 - 11/2006
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2009 - 04/2007
2	Biological ProductsIBA 06/2007 - 11/2006
1	fluoromisonidazoleIBA 05/2022
1	pembrolizumabIBA 05/2022
1	MethyltransferasesIBA 01/2022
1	MorpholinosIBA 01/2022
1	O-(6)-methylguanineIBA 01/2022
1	Antisense OligonucleotidesIBA 01/2022
1	Factor XI (Plasma Thromboplastin Antecedent)IBA 01/2022
1	Retinaldehyde (Retinal)IBA 01/2021
1	Mannitol (Osmitrol)FDA LinkGeneric 01/2021
1	ChemokinesIBA 01/2020
1	LipopolysaccharidesIBA 01/2020
1	AminoglycosidesIBA 01/2020
1	biocytinIBA 01/2020
1	Toll-Like Receptor 4IBA 01/2020
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020

Therapy/Procedure

33	Drug Therapy (Chemotherapy) 01/2021 - 05/2002
24	Therapeutics 01/2022 - 10/2003
9	Radiotherapy 01/2022 - 05/2006
6	Immunotherapy 05/2022 - 01/2005
6	Aftercare (After-Treatment) 02/2015 - 02/2005
4	Chemoradiotherapy 08/2014 - 01/2011
2	Injections 01/2020 - 04/2016